Chi-Shin Wu1, Susan Shur-Fen Gau2. 1. Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Psychiatry, Far Eastern Memorial Hospital, New Taipei City, Taiwan; 2. Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Brain and Mind Sciences, and Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan gaushufe@ntu.edu.tw.
Abstract
OBJECTIVE: Antipsychotic drug use is an established risk factor for the development of type 2 diabetes mellitus. However, the effect of antipsychotic drug on the progression of diabetes complications remains unclear. This study aimed to explore the association between antipsychotic treatment and advanced diabetes outcome among schizophrenia patients with type 2 diabetes. METHODS: The authors conducted a retrospective cohort study using Taiwan's universal health insurance database. A total of 17 629 schizophrenia patients with newly-diagnosed diabetes were enrolled. The mean duration of follow-up, after excluding the first 6-month observation period, was 4.8 years, ranged from 1 month to 11.5 years. Antipsychotic treatment patterns within a 6-month time window were classified into none, irregular use, and regular use. Antipsychotics were further categorized into the high, intermediate, and low metabolic risks. The status of exposure was treated as time-dependent variables. The outcomes measures included any advanced diabetes complications, macrovascular and microvascular complications, and all-cause mortality. RESULTS: Compared to no antipsychotic treatment in the past 6 months, regular antipsychotic use was associated with a lower risk of any advanced diabetes complications (adjusted hazard ratio, aHR = 0.81, 95% CI = 0.69-0.95), macrovascular complications (aHR = 0.80, 95% CI = 0.66-0.97), and all-cause mortality (aHR = 0.73, 95% CI = 0.62-0.85). The hazard ratios for advanced diabetes complications with regular use of antipsychotics with a high, intermediate, and low metabolic risk were 0.69 (95% CI = 0.53-0.91), 0.82 (95% CI = 0.68-0.99), and 0.85 (95% CI = 0.70-1.02), respectively. CONCLUSIONS: Regular antipsychotic treatment in the past 6 months was associated with reduced risks of any diabetes complications, compared to no antipsychotic treatment.
OBJECTIVE: Antipsychotic drug use is an established risk factor for the development of type 2 diabetes mellitus. However, the effect of antipsychotic drug on the progression of diabetes complications remains unclear. This study aimed to explore the association between antipsychotic treatment and advanced diabetes outcome among schizophreniapatients with type 2 diabetes. METHODS: The authors conducted a retrospective cohort study using Taiwan's universal health insurance database. A total of 17 629 schizophreniapatients with newly-diagnosed diabetes were enrolled. The mean duration of follow-up, after excluding the first 6-month observation period, was 4.8 years, ranged from 1 month to 11.5 years. Antipsychotic treatment patterns within a 6-month time window were classified into none, irregular use, and regular use. Antipsychotics were further categorized into the high, intermediate, and low metabolic risks. The status of exposure was treated as time-dependent variables. The outcomes measures included any advanced diabetes complications, macrovascular and microvascular complications, and all-cause mortality. RESULTS: Compared to no antipsychotic treatment in the past 6 months, regular antipsychotic use was associated with a lower risk of any advanced diabetes complications (adjusted hazard ratio, aHR = 0.81, 95% CI = 0.69-0.95), macrovascular complications (aHR = 0.80, 95% CI = 0.66-0.97), and all-cause mortality (aHR = 0.73, 95% CI = 0.62-0.85). The hazard ratios for advanced diabetes complications with regular use of antipsychotics with a high, intermediate, and low metabolic risk were 0.69 (95% CI = 0.53-0.91), 0.82 (95% CI = 0.68-0.99), and 0.85 (95% CI = 0.70-1.02), respectively. CONCLUSIONS: Regular antipsychotic treatment in the past 6 months was associated with reduced risks of any diabetes complications, compared to no antipsychotic treatment.
Authors: Scot H Simpson; Dean T Eurich; Sumit R Majumdar; Rajdeep S Padwal; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson Journal: BMJ Date: 2006-06-21
Authors: T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2011-07-18 Impact factor: 18.112
Authors: Robert D McQuade; Elyse Stock; Ron Marcus; Darlene Jody; Neveen A Gharbia; Simon Vanveggel; Don Archibald; William H Carson Journal: J Clin Psychiatry Date: 2004 Impact factor: 4.384
Authors: Shôn W Lewis; Thomas R E Barnes; Linda Davies; Robin M Murray; Graham Dunn; Karen P Hayhurst; Alison Markwick; Helen Lloyd; Peter B Jones Journal: Schizophr Bull Date: 2006-03-15 Impact factor: 9.306
Authors: Osamah Saeedi; Hasan Ashraf; Marc Malouf; Eric P Slade; Deborah R Medoff; Lan Li; Julie Kreyenbuhl Journal: Gen Hosp Psychiatry Date: 2016-08-18 Impact factor: 3.238
Authors: Chi-Shin Wu; Alex R Luedtke; Ekaterina Sadikova; Hui-Ju Tsai; Shih-Cheng Liao; Chen-Chung Liu; Susan Shur-Fen Gau; Tyler J VanderWeele; Ronald C Kessler Journal: JAMA Netw Open Date: 2020-02-05